Freedman, Rachel A. http://orcid.org/0000-0003-0460-674X
Revette, Anna C.
Gagnon, Haley
Perilla-Glen, Adriana
Kokoski, Molly
Hussein, Saida O.
Leone, Erin
Hixon, Nicole
Lovato, Rebeka
Loeser, Wendy
Lin, Nancy U.
Minami, Christina A.
Canin, Beverly
LeStage, Barbara
Faggen, Meredith
Poorvu, Philip D.
McKenna, Jennifer
Ruddy, Kathryn J.
Keating, Nancy L.
Schonberg, Mara A.
Funding for this research was provided by:
National Cancer Institute (R21CA227615-01A1)
Susan G. Komen (CCRCR18552788)
American Cancer Society (MRSG-14-240-01-CPPB)
National Institute on Aging (K24AG071906)
Article History
Received: 11 March 2022
Accepted: 4 July 2022
First Online: 30 July 2022
Declarations
:
: Nancy U. Lin reports institutional research funding from Genentech, Merck, Pfizer, Seattle Genetics, AstraZeneca, Zion Pharmaceuticals, and Olema Pharmaceuticals; consultant/advisory board work for Pfizer, Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Prelude Therapeutics, Denali Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, and Artera, Inc.; royalties from UpToDate; and stock or other ownership interests in Artera Inc. (a startup with no current value, but options only valued at < 5% and < $50,000 will be provided at a later date). The remaining authors declare that they have no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki and was approved by the DFCI Office of Human Research. Informed consent was obtained from all individual participants included in the study.
: Informed consent was obtained from all individual participants included in the study.
Free to read: This content has been made available to all.